ATE514424T1 - Pharmazeutische zubereitungen von taxanen - Google Patents

Pharmazeutische zubereitungen von taxanen

Info

Publication number
ATE514424T1
ATE514424T1 AT00903178T AT00903178T ATE514424T1 AT E514424 T1 ATE514424 T1 AT E514424T1 AT 00903178 T AT00903178 T AT 00903178T AT 00903178 T AT00903178 T AT 00903178T AT E514424 T1 ATE514424 T1 AT E514424T1
Authority
AT
Austria
Prior art keywords
taxans
pharmaceutical preparations
formulation
methylpyrrolidin
docetaxel
Prior art date
Application number
AT00903178T
Other languages
English (en)
Inventor
Frederick Hausheer
Dhanabalan Murali
Original Assignee
Bionumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE514424T1 publication Critical patent/ATE514424T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
AT00903178T 1999-01-08 2000-01-07 Pharmazeutische zubereitungen von taxanen ATE514424T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/226,968 US6040330A (en) 1999-01-08 1999-01-08 Pharmaceutical formulations of taxanes
PCT/US2000/000442 WO2000040238A1 (en) 1999-01-08 2000-01-07 Pharmaceutical formulations of taxanes

Publications (1)

Publication Number Publication Date
ATE514424T1 true ATE514424T1 (de) 2011-07-15

Family

ID=22851219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903178T ATE514424T1 (de) 1999-01-08 2000-01-07 Pharmazeutische zubereitungen von taxanen

Country Status (9)

Country Link
US (1) US6040330A (de)
EP (1) EP1061915B1 (de)
JP (2) JP5642913B2 (de)
CN (1) CN1169525C (de)
AT (1) ATE514424T1 (de)
AU (1) AU764626B2 (de)
CA (1) CA2321826C (de)
DK (1) DK1061915T3 (de)
WO (1) WO2000040238A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234472A1 (en) 2001-04-20 2004-11-25 Jackson John K. Micellar drug delivery systems for hydrophobic drugs
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
WO2002072150A2 (en) * 2001-03-13 2002-09-19 Angiotech Pharmaceuticals Inc. Micellar drug delivery vehicles and uses thereof
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
AU2002329842B2 (en) * 2001-08-29 2006-09-14 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CN1303994C (zh) * 2003-03-03 2007-03-14 浙江海正药业股份有限公司 紫杉醇囊泡注射剂及其制备方法
WO2005007129A2 (en) * 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
WO2005061474A1 (en) * 2003-12-12 2005-07-07 Quiral Química Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US20050129719A1 (en) * 2003-12-15 2005-06-16 Yu-Fang Hu Concentrated emulsion formulation for silatecan
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
WO2006036984A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Stand-alone film and methods for making the same
US8312836B2 (en) * 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US8263102B2 (en) * 2004-09-28 2012-09-11 Atrium Medical Corporation Drug delivery coating for use with a stent
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) * 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
WO2006119018A2 (en) * 2005-04-29 2006-11-09 Atrium Medical Corporation Drug delivery coating for use with a medical device and methods of treating vascular injury
EP1904052A4 (de) * 2005-06-17 2008-12-10 Hospira Australia Pty Ltd Flüssige pharmazeutische formulierungen von docetaxel
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) * 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
CA2626030A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
US9855279B2 (en) 2006-10-12 2018-01-02 Galera Labs, Llc Methods of treating oral mucositis
WO2008057328A2 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
EP2205215A2 (de) * 2007-10-01 2010-07-14 Intas Pharmaceuticals Limited Absolut ethanolfreie injizierbare docetaxelzusammensetzung
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US9724329B2 (en) * 2010-06-21 2017-08-08 Peter Maccallum Cancer Institute Stimulating immune response
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20120172796A1 (en) 2010-12-30 2012-07-05 Chappa Ralph A Composition for intravascular delivery of therapeutic composition
JP2013032332A (ja) * 2011-07-01 2013-02-14 Lintec Corp 免疫賦活剤
JP6267638B2 (ja) 2011-09-26 2018-01-24 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 疾患の治療方法
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
EP2777691A1 (de) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Reinigung der flüssigen Hilfsstoffen
IL297735B2 (en) 2015-08-11 2024-08-01 Galera Labs Llc Macrocyclic ring pentase complexes with oral bioavailability
KR20230075528A (ko) 2016-05-03 2023-05-31 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
EP3506907B1 (de) 2016-09-01 2023-06-07 Galera Labs, LLC Kombinierte krebstherapie mit einem pentaaza-makrocyclischen ring-komplex und einer ascorbatverbindung
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN107157926B (zh) * 2017-07-20 2020-08-21 四川汇宇制药股份有限公司 一种多西他赛注射剂的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes

Also Published As

Publication number Publication date
EP1061915A1 (de) 2000-12-27
WO2000040238A1 (en) 2000-07-13
AU2496300A (en) 2000-07-24
CA2321826A1 (en) 2000-07-13
JP5642913B2 (ja) 2014-12-17
CN1293570A (zh) 2001-05-02
AU764626B2 (en) 2003-08-28
JP2002534382A (ja) 2002-10-15
CN1169525C (zh) 2004-10-06
JP2010235636A (ja) 2010-10-21
JP5285663B2 (ja) 2013-09-11
US6040330A (en) 2000-03-21
EP1061915B1 (de) 2011-06-29
CA2321826C (en) 2007-12-04
EP1061915A4 (de) 2009-09-09
DK1061915T3 (da) 2011-10-03

Similar Documents

Publication Publication Date Title
ATE514424T1 (de) Pharmazeutische zubereitungen von taxanen
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
ECSP045411A (es) Derivados de quinolinona
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
NZ324801A (en) Oral pharmaceutical dosage form containing taxol or etoposide derivatives and a bioenhancer compound
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
DK1206261T3 (da) Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
EP0392745A3 (de) Immunokonjugate und Prodrogen und ihre gemeinschaftliche Anwendung für die Verabreichung von Arzneimitteln
ECSP083351A (es) Composiciones farmacéuticas
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
ATE292453T1 (de) Antivirale arznei
ATE329903T1 (de) Hochgradig lipophile camptothecin-derivate
BG66113B1 (bg) Комбиниран химиотерапевтичен състав
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
DE60045114D1 (de) Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
PE20010407A1 (es) Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
WO2003018535A3 (en) Novel aminobenzoephenones
CA2385755A1 (en) Prevention of colorectal cancer
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
Yeh et al. Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels
WO2004071398A3 (en) Pharmaceutical patch
HUP0301334A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és taxánokat és/vagy antimetabolitokat tartalmazó kombinált tumorellenes kompozíciók
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1061915

Country of ref document: EP